CRINETICS PHARM (CRNX)
(Delayed Data from NSDQ)
$33.91 USD
-1.57 (-4.43%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $34.01 +0.10 (0.29%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Crinetics Pharmaceuticals, Inc. has a market cap of $3.34B, which represents its share price of $35.48 multiplied by its outstanding shares number of 94.18M. As a mid-cap company, CRNX's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
CRNX 33.91 -1.57(-4.43%)
Will CRNX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CRNX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRNX
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline
CRNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last?
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates
Other News for CRNX
20 Day Moving Average Support appears for CRNX after 4.43% move
Interesting CRNX Put And Call Options For November 21st
CRNX forms MACD Bullish Signal Line Cross on September 19
Is CRNX positioned for a breakdown? MACD Bearish Signal Line Cross shows up after gaining 0.29%
The technical outlook for CRNX is unchanged after it rises 0.98% on September 16